bullish
Lotus Pharmaceutical (1795 TT): Continued Stellar Growth in Q2; Pipeline Expansion to Drive Growth
463 Views24 Sep 2023 08:47
SUMMARY
- In 2Q23, Lotus Pharmaceutical (1795 TT) reported 53% YoY growth in revenue to NTD4.4B, mainly driven by strong uptake of Lenalidomide and Suboxone in America and branded products in Taiwan.
- Lotus reported an EPS of NTD4.85 for Q2 2023, 285% above EPS of NTD1.26 reported for the same quarter of 2022. This result beat the average analyst’s estimate by NTD0.64.
- Lotus has acquired exclusive global right to develop and commercialize suicidal bipolar therapy NRX-101 and obtained approval for new branded oncology drug Zepzelca in Taiwan.
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »Loading
Top Unpaywalled Insights
More »Loading
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Lotus Pharmaceutical (1795 TT): Six Consecutive Years of Double-Digit Growth; Momentum to Continue20 Mar 2025
- Lotus Pharmaceutical (1795 TT): Record-High Performance in 2023; What Lies Ahead?21 Mar 2024
- Lotus Pharmaceutical Placement - Sound Fundamentals but Doesn’t Seem Well Flagged30 Jun 2023
- Lotus Pharmaceutical (1795 TT): 2022 Ends with Mid-Teen Revenue Growth; Further Steam Still Left05 Feb 2023
- Lotus Pharmaceutical (1795 TT): 3Q22 Review- Best-Ever Quarter, Aided by Oncology Drug Launch in US18 Nov 2022
x